Healthcare stocks edged lower late Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.2%.
The iShares Biotechnology ETF (IBB) increased 0.1%.
In corporate news, Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday. Merck shares were down 0.8%.